e-Article
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
Document Type
Short Communication
Author
Source
In Clinical Lung Cancer November 2012 13(6):500-504
Subject
Language
ISSN
1525-7304